COMPUESTOS COMO INHIBIDORES DE BACE

REFERIDO A COMPUESTOS DE FORMULA (I), DONDE: A ES -O- O -CH2-; n ES 0 O 1; R1 ES ALQUILO C1-6 O HALOALQUILO C1-6; R2 ES H, CIANO, HALOGENO, CIANO, ENTRE OTROS; R5 Y R6 SON INDEPENDIENTEMENTE HETEROCICLILO, ARILO, HETEROARILO, CICLOALQUILO C3-6, ALQUILO C1-6 OPCIONALMENTE SUSTITUIDOS, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 6-(3,5-DICLOROFENIL)-5�-METILESPIRO[CROMAN-4,2�-IMIDAZOL]-4�-AMINA; N-(4�-AMINO-5�-METIL-ESPIRO[CROMANO-4,2�-IMIDAZOL]-6-IL)-5-CLORO-PIRIDINA-2-CARBOXAMIDA; ENTRE OTROS. REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA BETA-SECRETASA, SIENDO UTILES PARA EL TRATAMIENTO DEL MAL DEL ALZHEIMER, DEMENCIA SENIL, HEMORRAGIA CEREBRAL HEREDITARIA, PERDIDA DE MEMORIA The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aß-related pathologies such as Down's syndrome, ß- amyloid angiopathy such as, but not limited to, cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.